Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL506406 | 0.98 | PARP1 (0.39) | CA1CA2PARP1TRPA1 | |
| Water SCHEMBL16428036 | 0.98 | CA1 (0.43) | CA1CA2PARP1TRPA1 | |
| Water SCHEMBL16428037 | 0.98 | CA1 (0.43) | CA1CA2PARP1TRPA1 | |
| Bromide SCHEMBL16698664 | 0.98 | CA1 (0.39) | CA1CA2PARP1TRPA1 | |
| Hydrochloric Acid SCHEMBL28783882 | 0.96 | CA1 (0.42) | CA1CA2PARP1 | |
| Succinic Acid SCHEMBL506729 | 0.85 | NOTUM (0.37) | CA1CA2TRPA1 | |
| Trifluoroacetic Acid SCHEMBL5455015 | 0.83 | CES1 (0.33) | CA1CA2 | |
| SCHEMBL29860173 | 0.79 | CA1 (0.38) | CA1CA2PARP1 | |
| SCHEMBL1227753 | 0.77 | CA1 (0.34) | CA1CA2PARP1TRPA1 | |
| SCHEMBL11843522 | 0.69 | PARP1 (0.33) | CA1CA2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101123955-B | 5HT2cReceptor modulator compositions and pharmaceutical uses thereof | ARENA PHARM INC | 2012-05-30 | — | — | CN | claimed |
| CN-101123955-A | 5HT2cReceptor modulator compositions and methods of use | ARENA PHARM INC (US) | 2008-02-13 | — | — | CN | claimed |
| EP-1554243-A1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LIMITED (GB) | 2005-07-20 | — | — | EP | claimed |
| WO-2004037788-A1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | claimed |
| EP-0153400-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF SUCH COMPOUNDS AND COMPOSITIONS | SCHERING CORPORATION (US) | 1985-09-04 | — | — | EP | claimed |
| WO-1985000808-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF SUCH COMPOUNDS AND COMPOSITIONS | SCHERING CORP. (US) | 1985-02-28 | — | — | WO | claimed |
| EP-0005299-A1 | Substituted 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines, process for the preparation thereof, and pharmaceutical compositions containing them | Technobiotic Ltd. (CH) | 1979-11-14 | — | — | EP | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250206708-A1 | AN OXAZIRIDINE PLATFORM FOR TARGETING FUNCTIONAL ALLOSTERIC METHIONINE SITES | NOVARTIS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| US-20250114351-A1 | 5-HT2C RECEPTOR MODULATING AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE, MENTAL, COGNITIVE AND AUTOIMMUNE CNS DISORDERS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2025-04-10 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-11872234-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11779587-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2003086306-A2 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-0603314-A4 | CHEMICAL COMPOUNDS. | SMITHKLINE BEECHAM CORP (US) | 1994-08-24 | — | — | EP | disclosed |
| EP-0603314-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-06-29 | — | — | EP | disclosed |
| EP-0022330-A2 | Synergistic antihypertensive compositions | SMITHKLINE BECKMAN CORPORATION (US) | 1981-01-14 | — | — | EP | disclosed |
| EP-0002327-A1 | Pharmacologically active 6-lower alkyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines, method of preparing them and intermediates | SMITHKLINE BECKMAN CORPORATION (US) | 1979-06-13 | — | — | EP | disclosed |
| US-4141894-A | ANALGESICS, ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1979-02-27 | — | — | US | disclosed |
| US-4141894-A | ANALGESICS, ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1979-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206708-A1 | AN OXAZIRIDINE PLATFORM FOR TARGETING FUNCTIONAL ALLOSTERIC METHIONINE SITES | MARCKS, PTMS, DMPK | CA1 4450/4885CA2 4690/4885PARP1 4812/4885 |
| US-11779587-B2 | Vareniciline compound and process of manufacture thereof | COMT, CYP2C9, CYP3A7 | CA1 4410/4885CA2 3873/4885PARP1 1066/4885 |
| US-11872234-B2 | Vareniciline compound and process of manufacture thereof | COMT, CYP2C9, CYP3A7 | CA1 4410/4885CA2 3873/4885PARP1 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.